



Soeren Galatius

Contact

Soeren Galatius

Publications (4)

Vassalli G, Pedrazzini G, Pfisterer M, Kaiser C, Moccetti T, Bonetti P, Bertel O, Hornig B, Rickli H, Eberli F, Erne P, Galatius S, De Servi S, Klersy C, BASKET-PROVE Investigators. Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial. *Am Heart J* 2015; 173:1-7.

Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. *Circulation* 2014; 131:74-81.

Kaiser C, Pfisterer M, Ricard I, Brunner-La Rocca H, De Servi S, Bonetti P, Bertel O, Hornig B, Pedrazzini G, Rickli H, Alber H, Eberli F, Erne P, Galatius S, BASKET-PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries. *N Engl J Med* 2010; 363:2310-9.

Pfisterer M, Kaiser C, De Servi S, Rickli H, Pedrazzini G, Pachinger O, Kiowski W, Hornig B, Galatius S, Erne P, Eberli F, Brunner-La Rocca H, Bonetti P, Bertel O, BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. *American heart journal* 2008; 155:609-14.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch